Neurocognition in youth with versus without prediabetes

JADE QUILLIAN[1], TUKI ATTUQUAYEFIO[1], JUSTIN SUNG[1], ANTONIETTA CANNA[2], TIFFANY KO[1], XUE DAVIS[1], KAITLIN MACIEJEWSKI[1], FANGYONG LI[1], NICOLA SANTORO[1], BRIDGET PIERPONT[1], STEPHANIE KULLMANN[3,4,6], HUBERT PREISSL[3,4,5,6,7], FILIP MORYS[2], ALAIN DAGHER[2], SONIA CAPRIO[1], DANA M SMALL[1, 2].

[1]Yale University, New Haven, CT, USA. [2]McGill University, Montreal, QC, Canada. [3]Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen/fMEG Center, Tübingen, Germany. [4]German Center for Diabetes Research (DZD), Tübingen, Germany. [5]German Center for Mental Health (DZPG), Partner Site Tübingen, Tübingen, Germany. [6]Division of Endocrinology, Diabetology and Nephrology, Department of Internal Medicine IV, University Hospital of Eberhard-Karls-University Tübingen, Tübingen, Germany. [7]Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry; Interfaculty Centre for Pharmacogenomics and Pharma Research at the Eberhard Karls University Tübingen, Tübingen, Germany.

ORCID Identifiers:
Jade Quillian - https://orcid.org/0000-0002-6371-8787
Tuki Attuquayefio - https://orcid.org/0000-0003-0328-1066
Justin Sung - https://orcid.org/0009-0006-9406-1817
Anonietta Canna - https://orcid.org/0000-0003-1058-9456
Tiffany Ko - https://orcid.org/0000-0002-5006-6345
Xue Davis - https://orcid.org/0009-0004-0853-2199
Kaitlin Maciejewski - https://orcid.org/0000-0002-6387-582X
Fangyong Li - https://orcid.org/0000-0003-3171-7592
Nicola Sontoro - https://orcid.org/0000-0001-6437-4173
Stephanie Kullmann - https://orcid.org/0000-0001-9951-923X
Hubert Preissl - http://orcid.org/0000-0002-8859-4661
Filip Morys - https://orcid.org/0000-0001-8996-2676
Alain Dagher - https://orcid.org/0000-0002-0945-5779
Sonia Caprio - https://orcid.org/0000-0002-7523-5053
Dana Small - https://orcid.org/0000-0001-7363-1100

Please address all correspondence to:
Dana M. Small, PhD phone: (514) 934-1934 Email: dana.small@mcgill.ca
McGill University
Center for Translational Biology,
RI-MUHC, Glen Site, 1001 Decarie Blvd., Bloc E, Montreal, QC H4A 3J1
Montreal Neurological Institute
NW 256
3801 rue University, Montreal, QC H4A 1B1.

Manuscript current word count: 5560 words

Abstract

Aims/Hypothesis: Type 2 diabetes has a well-established link to cognitive impairment in older adults; however, studies often do not control for adiposity and co-morbid conditions which might mediate this cognitive impairment. To overcome these limitations, we investigated the relation between prediabetes and cognition in youth with overweight/obesity while controlling for adiposity in a cross-sectional ancillary study to the Pathogenesis of Youth Onset Diabetes (PYOD) study. We reasoned that if glucose control directly impacts brain health, then cognitive function should be worse in youth with versus without prediabetes. We also predicted that this effect should be greater on tasks that depend on dopaminergic function, such as working memory and that it may be related to central insulin sensitivity.

Methods: We evaluated 69 youth with overweight/obesity for anthropomorphic and metabolic measures, abdominal adiposity, comprehensive cognitive testing, and the effects of intranasal insulin on cognition, resting state brain activity, and functional connectivity. Oral glucose tolerance tests classified 22 participants as having prediabetes (preT2D+) and 44 participants as having normal glucose control (preT2D-).

Results: Groups did not differ in age, sex, race, diet, or adiposity measures. IQ was significantly lower ($p=0.032$) in the preT2D+ group compared to the preT2D- group. The preT2D+ group performed worse than the preT2D- group in tasks of working memory ($p<.0.001$), reaction time ($p=0.01$), and visuospatial processing ($p=0.02$). After considering IQ as a model covariate, only spatial working memory showed a significant difference between groups ($p=0.002$). Insulin sensitivity across the entire sample was negatively correlated with processing speed in two tasks (reaction time index: $p=0.022$; and trail making test A: $p=0.022$) and with the sensitivity of the intraparietal sulcus to intranasal insulin administration. Administration of intranasal insulin showed no effect on cognition within or between groups. However, the extent to which intranasal insulin administration influenced caudate functional connectivity with the right intraparietal sulcus ($p_{(FWE)}=0.018$) and bilateral medial precuneus ($p_{(FWE)}=0.03$) was correlated with performance on the spatial working memory task.

Conclusions/interpretation: We find evidence for the presence of global cognitive impairment in youth with prediabetes that cannot be accounted for by adiposity, as well as a specific deficit in spatial working memory that is not attributable to global cognitive impairment. We identified associations between central insulin sensitivity and both cognition and peripheral insulin sensitivity; however, central insulin sensitivity did not appear to account for the effect of prediabetes on cognition. These findings show that the association between peripheral glucose intolerance and cognition exists early in the course of the disease, prior to the onset of significant comorbid conditions and independently of adiposity. It also suggests the involvement of both generalized and specific mechanisms contributing to cognitive change.

Keywords

Adiposity, BMI, Brain health, Cognition, IQ, Intranasal insulin, Intraparietal sulcus, Prediabetes, Resting state fMRI, Type 2 diabetes, Working memory.

Abbreviations

Resting state functional magnetic resonance imaging – rsFMRI; Oral glucose tolerance test – OGTT; mild cognitive impairment – MCI; dopamine – DA; insulin resistance – IR; body mass index – BMI; intranasal insulin – INI; Fractional Amplitude of Low Frequency Fluctuations – fALFF;

Research in Context

- **What is already known about this subject? (maximum of 3 bullet points)**
  - Type 2 diabetes and prediabetes have been associated with an increased risk of dementia and cognitive impairment on dopaminergic tasks
  - The mechanism of this cognitive impairment and if it is dissociable from adiposity or comorbid conditions related to old age is unknown
  - It is unclear whether youth with prediabetes are at risk for cognitive impairment from impaired insulin sensitivity/glucose regulation
- **What is the key question? (one bullet point only; formatted as a question)**
  - Do youth with prediabetes show cognitive impairment independent of adiposity, and is this related to insulin sensitivity of dopaminergic systems?
- **What are the new findings? (maximum of 3 bullet points)**
  - Youth with prediabetes show global cognitive impairment, as well as particular impairment of spatial working memory, independent of adiposity
  - Insulin sensitivity of caudate functional connectivity with right intraparietal sulcus and bilateral precuneus is correlated with prior performance on a spatial working memory task
- **How might this impact on clinical practice in the foreseeable future? (one bullet point only)**
  - These findings provide evidence that suggests that youth with prediabetes are at risk for cognitive impairment, indicating early detection and treatment of impaired insulin sensitivity is crucial.

INTRODUCTION

It is has been well established that type 2 diabetes is associated with cognitive impairment and with dementia in later life[1], [2], [3]. A recent meta-analysis found the estimated prevalence of mild cognitive impairment (MCI) in adults with type 2 diabetes to be 45%[4], while other studies have found the relative risk of dementia is 50% higher in those with versus without type 2 diabetes[2]. In 2021, an estimated 32.2 million adults in the United States and 535.6 million adults globally (10.5%) had diabetes, with those numbers predicted to increase by 2045 to 36.3 and 783.2 million (12.2%) respectively[5]. It is estimated that 96% of those cases are type-2 diabetes mellitus[6], and the prevalence of type 2 diabetes among adolescents has almost doubled from 2001 to 2017 from 0.34 to 0.67 per 1000 adolescents below 20 years old[7]. With the increasing prevalence of type 2 diabetes, the personal and societal burden of associated cognitive impairment is a growing concern.

Multiple complications of type 2 diabetes have been proposed as the driving force behind cognitive decline, though whether there is a direct causal mechanism remains unclear. Chronic hyperglycemia is associated with increased risk of dementia and higher 2h glucose and HbA1c have been correlated with degree of cognitive deficit[8], [9]. This may result from micro and macro vascular complications that have been associated with hyperglycemia[3], [10]. Hyperinsulinemia and central IR have been linked to mitochondrial dysfunction[11], neuroinflammation[12], [13], [14], disruptions of the blood brain barrier[13], [14], [15], and may influence the amyloid beta pathophysiological process[16]. The metabolic disruptions in type 2 diabetes may promote cerebrovascular damage over time via these complications, but it remains unclear if cognition is only impaired in type 2 diabetes by such secondary effects, or if there are more direct effects in the brain under type 2 diabetes that impair cognition. For example, impaired central insulin sensitivity is present in both type 2 diabetes and Alzheimer's disease[16], implicating its role in cognitive decline.

Inferences about pathophysiology can also be made by considering the overall neuropsychological profile associated with type 2 diabetes. Type 2 diabetes-associated cognitive decline is typified by impairment in executive function, psychomotor speed, attention, and memory[10], [17]. Prediabetes, in which individuals show impaired insulin sensitivity and less severe hyperglycemia, has also been associated with a specific impairment in a task of complex attention and executive function[18]. The impaired cognitive domains for both type 2 diabetes and prediabetes rely heavily on DA signaling, indicating that DA systems may be directly affected by these conditions. A recent study by Kullmann *et al*. (2021) demonstrated that administration of intranasal insulin (INI) affects dopamine signaling in the striatum, and that greater sensitivity of the DA signaling to INI was related to increased mesocorticolimbic functional connectivity after INI administration and greater baseline cognitive restraint and overall well-being[19]. This could explain improvements in cognitive function seen in studies where INI has been administered to participants with AD and mild cognitive impairment[20], [21], and points towards impaired central insulin sensitivity impacting DA signaling as a potential major contributing factor to cognitive decline in type 2 diabetes. If so, then dopamine

dependent cognitive functions such as working memory may be relatively more impaired. For example, animal research has shown impaired insulin signaling in the brain can lead to decreased dopamine signaling in the caudate[22], a primary target of midbrain dopamine neurons that is critical for executive functioning tasks such as spatial working memory[23]. We therefore predict that central and peripheral insulin sensitivity may be associated with dopamine dependent cognition via effects on dopaminergic circuit function.

Also of importance in trying to elucidate the mechanisms of cognitive function in type 2 diabetes is the role of adiposity and age, since both factors may contribute independently to many of the potential mechanisms outlined above. The majority of human studies linking type 2 diabetes with cognitive decline have been performed in older adults[1], who are more likely to have long-standing diagnoses of type 2 diabetes and associated comorbid conditions such as damage to the blood brain barrier, neuroinflammation[24], [25], cerebral atrophy, and small vessel disease[26], [27], [28], [29]. In addition, adiposity is often not evaluated or included in models as a potential contributor or confound[30], [31], [32], [33], [34], despite longstanding evidence that adiposity is also associated with cognitive impairment and dementia[35], [36], [37]. These complicating factors make it difficult to decipher the extent to which type 2 diabetes, without secondary or comorbid issues, leads to cognitive impairment, and what the specific mechanisms of that impairment may be.

To address these issues, in the current study we recruited participants from the Pathogenesis of Youth Onset Diabetes study (PYOD), a cohort of youth with overweight and obesity but varying levels of glucose tolerance and insulin sensitivity. Since the cohort includes youth, who lack potential long-term effects of type 2 diabetes and comorbid diseases that come with age, we minimize the contribution of these potential confounds. Moreover, the cohort enables direct comparisons to be made between youth with versus without prediabetes while controlling for adiposity. We performed a comprehensive cognitive assessment and used resting-state functional magnetic resonance imaging (rsfMRI) to evaluate resting state brain activity before and after INI to assess central insulin sensitivity. We hypothesized that youth with, versus without a diagnosis of prediabetes, would have reduced performance on dopamine-dependent cognition, including executive functioning, psychomotor speed, and temporal discounting, but not other domains of cognitive functioning such as verbal comprehension, visuospatial processing, and short-term visual memory. We also predicted specifically that cognitive impairment on a dopamine dependent task (working memory) would be associated with rsfMRI connectivity in the caudate nucleus and that this effect would be sensitive to INI, reflecting reduced central insulin sensitivity in dopaminergic networks.

Methods

Overall study description

The current report focuses on data collected during the baseline assessment of a two-year observational study in youth with overweight/obesity recruited primarily from the PYOD (Fig. 1a; see electronic supplementary material [ESM] Methods for full longitudinal protocol). The

baseline assessments consisted of an intake, an OGTT and body composition measurement day, a comprehensive neuropsychological testing day, and two days of MRI scanning (Fig. 1b)

Participants

Adolescents with obesity (BMI above 85th percentile) aged 8-20 were recruited from the ongoing PYOD study at Yale University and from physician referrals at Yale obesity outpatient clinics (see EMS Methods for inclusion/exclusion criteria). All participants provided written informed consent/assent and were compensated. Those under 18 assented and parental consent was obtained. The study was conducted in accordance with the standards laid out in the Declaration of Helsinki. The study procedures were approved by the Yale Human Investigations Committee (Institutional Review Board Protocol no. 2000020794). The study was also preregistered on 23 January 2018, to AsPredicted.org under access no. 7968, available at: https://aspredicted.org/ypx5-t6bp.pdf.

We had originally planned to complete 94 baseline assessments based on a power calculation for a 24-month analysis requiring 80 completers; however, enrollment and retention were negatively impacted by the COVID-19 pandemic. Sixty-nine participants completed all baseline assessment sessions. A flow diagram depicting the number of participants from enrollment until baseline completion and analysis is depicted in Fig. 2.

Participants were classified as having prediabetes (preT2D+) or no prediabetes (preT2D-) based on fasting glucose, 2h glucose, and HbA_{1C}, as detailed in the OGTT section below. This resulted in 44 preT2D- and 22 preT2D+. One subject could not be classified due to missing OGTT data. Two subjects were excluded from analysis for having OGTT measurements (fasting glucose and 2h glucose) in the diabetic range.

Intake Session

After consent/assent was obtained from participants, and parents when appropriate, participants underwent a mock MRI scan to familiarize them with the scanning environment, completed the Cambridge Automated Neuropsychological Test Battery (CANTAB; Cambridge Cognition Ltd) suite of tasks used in the study, and were administered an intranasal spray of saline to simulate the intranasal administration of insulin used in the study. Demographic data was collected at this session from participants or their parents.

Day 1: OGTT Session

Participants arrived after an overnight fast. First, body composition measurements were taken (ESM Methods for details). Age and sex adjusted BMI z-score and BMI 95th percentile score were calculated according to CDC growth charts (https://www.cdc.gov/nchs/data/series/sr_11/sr11_246.pdf). A 75g glucose OGTT was performed (ESM Methods for details). Participants were classified as preT2D+ if they had two or three of the following impairments: impaired HbA_{1C} (>5.6), impaired fasting glucose (fasting glucose >100 mg/dl), and impaired glucose tolerance (2h glucose >140 mg/dl in the OGTT). HOMA-IR was calculated using the following formula: (fasting glucose(mg/dL) * fasting

insulin(µU/mL)/405. Matsuda index was calculated using insulin/glucose levels from five timepoints.[38]

Day 2: Neuropsychological Assessment

Neuropsychological testing was conducted by trained staff in a quiet and distraction-free environment. Assessments performed are listed in Table 2 (ESM Methods for details). Due to ceiling effects on the original CANTAB spatial working memory task version used (4, 6, and 8-box trials), an extended 12 box version was added after the first 21 subjects had completed this portion of the study. Only results from the 12-box version are used in this study's analyses.

Days 3-4: Scanner Days - Anatomical and Functional Neuroimaging

Participants arrived having fasted for at least two hours. Sessions began with anatomical images of the abdomen or head. Functional scans followed as depicted in Fig. 1b, with two 6-min resting state functional magnetic resonance imaging (rsfMRI) scans, flanking (pre-/post spray scans) either INI (Humulin R human insulin 100 IU/ml, Lilly) or placebo plus a 15-min rest. Participants were taken out of the scanner for the INI/placebo spray. Insulin dose was of 1 IU per kg rounded to multiples of 10 IU (10, 20, 30 IU etc) up to a maximum of 60 IU, or an equivalent volume of sterile saline solution as placebo.[39] Insulin and placebo were administered using a syringe with an attached atomizer, spraying small puffs of solution into alternating nostrils while gently inhaling through the nostrils until the entirety of the solution had been inhaled. Immediately following the post-spray rsfMRI scan, participants were taken to a private testing room and completed a CANTAB test battery. The order in which participants received INI or placebo on the two scanner days was counterbalanced across subjects.

MRI acquisition

Anatomical and neuroimaging data were acquired on a Siemens Prisma 3 Tesla scanner at the Yale University Magnetic Resonance Research Center. Visceral and subcutaneous fat (deep and superficial) were assessed with a T1-weighted fast spin-echo sequence images of the abdomen. Proton Density Fat Fraction (PDFF) MRI liver images were acquired to assess liver fat fraction.

To assess resting-state functional connectivity, whole-brain BOLD data were collected using multiband accelerated echo-planar imaging sequences, developed at Center for Magnetic Resonance Research (CMRR) Minnesota, USA. The functional images were acquired with TR = 1500 ms, TE = 34 ms, flip angle = 70°, FOV = 192, partial Fourier=6/8, bandwidth= 1860 Hz/Px, echo spacing = 0.66 ms, matrix = 96 × 96, voxel size = 2× 2× 2 mm, images were acquired in interleaved order with a multiband acceleration factor of 4. Two other multi band scans with antero-posterior and poster-anterior phase encoding directions were acquired for distortion correction.

Behavioral analysis

Statistical analysis was run using R studio (version 2024.12.1). OGTT data was missing from one participant, and two participants were excluded for glucose values in diabetic range, thus behavioral analyses were performed with 66 of the 69 datasets. Cook's distance was used to identify outliers in the data, revealing one outlier subject with significantly longer completion

times for TMT A and TMT B tasks. Final analyses were completed for these tasks without this subject included.

Missing Data

Dietary Fat and Sugar surveys were missing responses on one item for six participants, and for two items for one subject, due to subjects skipping these questions. Scores for these missing data points were interpolated by calculating the mean response score for the subject within the relevant item category (sugar, fat, or sugar-and-fat). Otherwise, subjects with missing data for a given measure were excluded from analyses of that measure. Total household income was collected as a measure of socioeconomic status, but was not included our analyses because 18 subjects declined to respond. Group comparison of available data did not indicate differences in socioeconomic status (see ESM Table 1 for data and comparison).

Demographics and baseline variables by prediabetes status:

Effects of group (preT2D+ vs preT2D-) were calculated using Welch Two Sample t-test, Pearson's Chi-squared test, or Fisher's exact test as appropriate. Variables tested for baseline group differences are listed in Table 1. Variables with a $p < 0.10$ were planned to be included as covariates in subsequent analyses, with IQ being the only one to reach this threshold ($p=0.032$).

Association between adiposity and metabolic measures:

To determine the associations between adiposity and metabolic measures, we ran Pearson correlations across measures and created a correlation matrix using GraphPad Prism 9 software (GraphPad Software 2021).

Data Visualization:

Graphs were made using GraphPad Prism 9 (GraphPad Software 2021). MRI visualizations were made using MRIcroGL (obtained from https://www.nitrc.org/projects/mricrogl/).

Cognition:

Group differences in cognition across domains:

Linear regressions were run to assess group differences in performance on tasks of various cognitive domains (see Table 2 for task-domain classification), both without covariates (model 1) and with IQ as a covariate (model 2) so that we could identify deficits relative to IQ. Benjamini-Hochberg correction (BHC) was applied to domains with multiple measures to account for multiple comparisons.

Scanner Days: Effects of intranasal insulin (INI) administration:

The effect of insulin on cognitive performance within and between groups was assessed for the CANTAB battery (stop signal task not included in this testing for time). Linear mixed model analyses were used to investigate the effect of group (preT2D-/preT2D+), condition (INI/Placebo) and group by condition interactions. The models included participant ID as a random effect to account for the repeated measurements done on each participant (insulin vs placebo).

Effects of peripheral insulin sensitivity on cognition (exploratory analyses):
We performed exploratory linear regressions on Matsuda index's relation to cognition across the full sample with age and BMI z-score as covariates (see ESM Methods for measures tested).

We performed linear mixed model analyses to assess the effects of interactions between condition (insulin vs placebo) and Matsuda index on performance on the CANTAB battery assessed on the imaging days. Age and BMI z-score were used as covariates.

Neural Correlates:

MRI data preprocessing
Functional data were preprocessed using DPARSF v. 5.4 (https://rfmri.org/DPARSF), spm12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/) running on MATLAB 2016a and FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslInstallation). Sample size was limited by subject exclusions due to excessive motion in scanner and available data for main effects. See ESM Methods for motion exclusion and preprocessing pipeline details. Table 3 summarizes sample sizes for analyses run on rsfMRI data.

Fractional Amplitude of Low Frequency Fluctuations (fALFF) analyses:
To assess the impact of INI of resting state brain activity, fractional amplitude of low frequency fluctuations[40] was implemented in the DPARFS toolbox. The relative intensity of BOLD fluctuations at rest in a given area was determined by the ratio of the power spectrum of the defined low-frequency range (0.01-0.1Hz) taken in relation to the power of the entire frequency range (0-0.25Hz). As previously suggested,[41] data without temporal filtering were used to compute the fALFF maps.

Statistical analyses were performed in SPM12. First, we used a full factorial design that included time (2 levels, pre and post intranasal injection), condition (2 levels: placebo and INI), and group (2 levels: preT2D+ and preT2D-) as within subjects' factors and age, sex, and BMI z-score as covariates for the subgroup of participants where all four scans passed our criterion for acceptable movement (preT2D- n=19, preT2D+=9). The statistical F map of the interaction between scans and conditions was computed and the resulting clusters of significant effects were extracted using a statistical threshold of $p<0.001$ at voxel level and corrected at cluster level using the family-wise error (FWE).

To increase our sample size, we limited further analyses to post-spray scans. This enabled us to include additional subjects with acceptable movement from their two post-spray scans (preT2D- n=28, preT2D+ n=13). Multiple regression analyses were performed to determine the relation between INI's effect on resting state activity and variables of interest related to metabolic health and cognition. These main analyses did not look at group due to the small preT2D+ sample size. First, the difference in fALFF values between insulin and placebo conditions was calculated for each subject in SPM using a voxel-based subtraction of the post-insulin scan minus the post-placebo scan. The resulting insulin-placebo maps were used in a multiple regression analysis with Matsuda index (n=41), using age, sex, and BMI z-score as covariates. Using the same covariates, multiple regression analyses were run on scores from

tasks conducted during the neuropsychological testing session where significant differences were observed between groups; spatial working memory (n=28), reaction time index (n=40), and block design (n=42). Finally, the difference in the scores from the four tests completed on rsfMRI scan days (spatial working memory, delayed match-to-sample, pattern recognition memory, and reaction time index) were calculated for post-insulin minus post-placebo, and multiple regression analyses were run, again using age, sex, and BMI z-score as covariates. Contrast estimates were extracted from the peak voxel of every significant cluster for each of these analyses from the insulin-placebo maps to be plotted against their relevant variables for visualization of the direction of associations.

Seed-based caudate connectivity analyses:
To assess the impact of INI on DA-dependent signaling and cognitive function, seed-based analyses of caudate connectivity were employed. For each participant, seed-based correlation maps were computed using the Pearson correlation between the signal time course of each voxel and the mean signal time course in the seed, located in the bilateral caudate and obtained using the *wfu_pickatlas* tool (https://www.nitrc.org/projects/wfu_pickatlas). Finally, the correlation values were transformed in z-values using Fisher Transformations.

In the same manner as above with the fALFF analysis, insulin-placebo maps were calculated for each subject and regression analyses were run to determine effects of condition and group on caudate connectivity under intranasal insulin. Regressions were run for scores from the three tasks from the neuropsychological test day that showed significant differences and for all four tests completed on the rsfMRI scan days.

RESULTS

Demographics and baseline variables by prediabetes status:
PreT2D- (n=44) and preT2D+, (n=22) groups did not differ on any of the demographic, dietary, adiposity, sleep, or depression measures ($p \geq 0.1$). Mean Full Scale IQ differed significantly between groups (Fig. 4a, $t(57.6) = 2.2$, mean difference = 7 95% CI [0.64, 13], $p = 0.032$), with the preT2D+ group (mean=92, SD=10.41) scoring lower than the preT2D- group (mean = 99 ± 15.16). Insulin sensitivity, as measured by Matsuda index, in preT2D+ (mean = 1.07± 0.42) was significantly lower (Fig. 4b, $t(62) = 3.31$, mean difference = 0.57 95% CI [0.23, 0.92], $p = 0.002$) than in preT2D- (mean = 1.67 ± 0.97). Full results reported in Table 1.

Association between adiposity and metabolic measures:
Matsuda Index correlated with almost all measures of both glucose metabolism and adiposity (Fig. 3). Conversely, HbA1c did not correlate with any tested measures. HOMA-IR correlated with both BMI-z score and measures of abdominal adiposity. Adiposity measures were highly correlated within themselves.

Cognition:

Group differences in cognition across domains:
Linear regressions comparing group performance on tasks from the Neuropsychological Assessment across cognitive domains (Table 2) revealed impaired task performance in executive functioning, psychomotor speed, and visuospatial processing in preT2D+ compared to preT2D-(Fig. 5a-c). Specifically, preT2D+ had more errors on the spatial working memory task (Fig. 5a, preT2D+ mean = 40 ± 3.25, preT2D- mean = 24.66 ± 2.41, mean difference = 15.3 95% CI [7.18, 23.51], t(43) = 3.79, $p < 0.001$). Reaction time was slower on reaction time index in preT2D+ compared to preT2D- (Fig. 5b, preT2D+ mean = 291.57 ± 12.26, preT2D- mean = 251.81 ± 8.67, mean difference = 39.76 95% CI [9.73, 69.79], t(61) = 2.64, $p = 0.01$) and block design score was lower in preT2D+ compared to preT2D- (Fig. 5c, preT2D+ mean = 8.41 ± 0.58, preT2D- mean=10.09 ± 0.41, mean difference = -1.68 95% CI [-3.09, -0.27], t(64) = -2.38, $p = 0.02$). After including IQ as a covariate in the regressions, only spatial working memory significantly differed between groups (mean difference = 13.42 95% CI [5.05, 21.80], t(42) = 3.23, $p = 0.002$).

Scanner Day: Effects of intranasal insulin (INI) administration:
The effect of INI on cognition was assessed using linear mixed models. We observed a significant effect of group on reaction time index performance (F(1,64)=3.89, $p = 0.047$), but no significant effects of condition on performance or two-way interactions between group and condition on task performance.

Effects of peripheral insulin sensitivity on cognition (exploratory analyses):
Since group sizes were smaller than planned, we also regressed Matsuda index scores against cognitive measures assessed during the neuropsychology day using age and BMI-z score as covariates. The only significant effects to emerge were negative associations between Matsuda index and scores on reaction time index (Fig. 5d, β = -21.09 95% CI [-38.9, -3.11], t(58) = -2.349, $p = 0.022$) and Trail Making Test A (Fig. 5e, β = -3.28 95% CI [-6.07, -0.429], t(60) = -2.353, $p = 0.022$).

No significant effects were observed from the generalized linear mixed models assessing associations between peripheral insulin sensitivity and cognitive performance under INI.

Neural Correlates:
fALFF- Peripheral metabolic health and central insulin sensitivity:
We first examined effects of group and INI on resting state activation using fALFF. A Full Factorial analysis {factors = group (preT2D+, preT2D-), time (pre-spray, post-spray) and condition (insulin, placebo)} was performed for the subgroup of participants where all four scans passed our criterion for acceptable movement (preT2D- n=19, preT2D+=9). Age, sex, and BMI z-score served as covariates for all rsfMRI analyses. There was a main effect of group in the left intraparietal sulcus (Montreal Neurological Institute [MNI] coordinates: -26, -42, 40; k=85; $p_{(FWE)}$ =0.035), with greater activity in preT2D+ compared to preT2D- (Fig. 6a and 5b). A three-way interaction was also observed in the right occipital cortex (MNI coordinates: 30, -84, 22; k=82; $p_{(FWE)}$ =0.041) with greater activity in preT2D- compared to preT2D+ in Insulin (pre-spray minus post-spray) versus Placebo (pre-spray minus post-spray) (Fig. 6c).

To increase our sample size, we limited further analyses to post-spray scans. This enabled us to include additional subjects with acceptable movement from their two post-spray scans (preT2D- n=28, preT2D+ n=13). To assess effects of peripheral insulin sensitivity across the entire sample (n = 41), we regressed Matsuda index against resting state brain activity (fALFF) in insulin minus placebo. This identified a positive correlation between peripheral insulin sensitivity and central insulin sensitivity in the intraparietal sulcus (MNI coordinates: -26, -52, 40; k=54; $p_{(FWE)}$ =0.048) (Fig. 6e).

fALFF- Effects related to cognition:

Analysis of the neuropsychological data identified an impact of peripheral glucose control on spatial working memory, reaction time index and block design. To identify potential neural correlates for these cognitive effects we regressed performance on these tasks from the in-lab assessment on resting state activation on the contrast of insulin vs placebo. The only effect to emerge was with the reaction time index task. Considering all participants (n = 40), insulin vs placebo activation in the right medial prefrontal cortex (MNI coordinates: 12, 56, 2; k=61; $p_{(FWE)}$ =0.032) was inversely associated with reaction time (Fig. 7a and b). This analysis was repeated post-hoc within each group separately to try to possibly understand if one or both groups were driving this effect. In preT2D- (n = 27), a significant cluster was identified that overlapped with the activity from the full group analysis (MNI coordinates: 12, 58, 4; k=53; $p_{(FWE)}$ =0.036) (Fig. 7a). There was a small cluster in the preT2D+ group just anterior to the full sample cluster (MNI coordinates: 8, 64, 14; k =25; $p_{(FWE)}$ =0.062) (Fig. 7a), but this was not significant.

Next, we tested for associations with cognitive data collected on the scan days. Specifically, we regressed difference scores (insulin scores minus placebo scores) for each task against the contrast of activation from insulin versus placebo. We identified a negative association between reaction time index and sensitivity of the left anterior superior temporal gyrus to insulin (MNI coordinates: -40, 0, 14; k=72; $p_{(FWE)}$ =0.014) (Fig. 7c) such that greater increase in activity under insulin compared to placebo was associated with faster reaction time in insulin vs. placebo. A positive association was observed for pattern recognition memory and the sensitivity of the left anterior dorsal insula to insulin (MNI coordinates: -38, 0, 12; k=59; $p_{(FWE)}$ =0.025) (Fig. 7e) such that greater increase in activity under insulin compared to placebo was associated with better pattern recognition memory in insulin vs. placebo.

Caudate connectivity and spatial working memory performance:

Finally, to test our hypothesis that DA-specific central insulin sensitivity would show a correlation between working memory and caudate signaling, we performed connectivity analyses using the caudate as a region of interest. Spatial working memory score from the neuropsychological testing day was regressed against caudate connectivity in insulin (post-spray) versus placebo (post-spray) (n = 28). A negative correlation between number of errors and caudate connectivity was observed in the right intraparietal sulcus (MNI coordinates: 38, -56, 58; k=127; $p_{(FWE)}$ =0.018) (Fig. 8a and b) and bilateral precuneus (MNI coordinates: 6, -62, 44; k=114; $p_{(FWE)}$ =0.03) (Fig. 8a and c). When repeating the analysis for each group individually,

no significant associations were found between spatial working memory task performance and caudate connectivity responsiveness to insulin in the preT2D+ group (n=9), but the preT2D- (n=18) group showed associations in bilateral precuneus (MNI coordinates: -8, -76, 52; k=105; $p_{(FWE)}$ =0.015)(MNI coordinates: 16, -68, 44; k=137; $p_{(FWE)}$ =0.003), left intraparietal sulcus(MNI coordinates: -38, -52, 40; k=98; $p_{(FWE)}$ =0.021), right dorsolateral prefrontal cortex (MNI coordinates: 40, 30, 30; k=91; $p_{(FWE)}$ =0.031), and right fusiform (MNI coordinates: 33, -38, -16; k=213; $p_{(FWE)}$ <0.001) (Fig. 8d).

Discussion

Type 2 diabetes is associated with cognitive impairment and increased risk for dementia, but the mechanisms behind the association are uncertain. One factor contributing to this uncertainty is the presence of comorbid conditions such as obesity and cardiovascular disease that might also impact cognitive function. Here, we address this shortcoming by examining cognition in youth with overweight or obesity who do or do not have a diagnosis of prediabetes. We report that after accounting for adiposity, prediabetes is associated with impaired overall cognition (IQ), as well as specific deficits in tasks of executive function, psychomotor speed and visuospatial processing. We identified associations between central insulin sensitivity and both cognition and peripheral insulin sensitivity; however, central insulin sensitivity did not appear to account for the effect of prediabetes on cognition. These findings show that the association between peripheral glucose intolerance and cognition exists early in the course of the disease, prior to the onset of significant comorbid conditions and independently of adiposity.

Several studies have reported deficits in global cognition in individuals with type 2 diabetes[9], [42], [43]. However, they often fail to account for adiposity and tend to only include subsets of cognitive measures. For example, a meta-analysis identified a risk of global cognitive decline across 144 studies but did not account for adiposity[9],whereas a study in adolescents with obesity reported lower estimated full-scale IQ in participants with type 2 diabetes but the estimate was derived from only two subtests of the Weschler Abbreviated Scale of Intelligence[42]. The results of the current study agree with these reports and rule out effects of adiposity while also using a more comprehensive assessment. One issue that remains outstanding is causality. It is possible that those with lower IQ may be more vulnerable to the development of prediabetes or that poor glucose control results in changes in global cognitive ability. A second consideration is the possibility that impaired glucose control during adolescence might be particularly harmful for brain development. Supporting this possibility, age of onset of type 1 diabetes is associated with magnitude of cognitive impairment[44].

In the current study we also assessed central insulin sensitivity using an INI protocol in conjunction with rsfMRI[39]. A complex relationship between central and peripheral insulin sensitivity was observed in the intraparietal sulcus. First, irrespective of condition (placebo versus INI), individuals with versus without prediabetes showed greater response in this region (Fig. 6a and b). This suggests that reduced peripheral sensitivity is associated with higher

intraparietal sulcus activity. This is consistent with a prior report that individuals with type 2 diabetes and high dietary restraint show greater responses in the intraparietal sulcus to food cues[45]. However, across the entire sample (preT2D+ and preTD2-) Matsuda index, a measure of whole-body insulin sensitivity, was positively associated with the effect of INI versus placebo on intraparietal sulcus activity (Fig. 6e). Visual inspection of the scatterplot depicting this response suggests that this effect is driven primarily by individuals with high whole body insulin sensitivity. Specifically, INI increased activity in this region over placebo in those with high peripheral insulin sensitivity. This suggests that INI only influences intraparietal sulcus response if peripheral insulin sensitivity is high; however, few participants in either group had high peripheral insulin sensitivity. For example, a Matsuda index below 2.5 is considered as high risk for impaired insulin sensitivity[46] and 61/66 participants fell in this range. These results indicate that those with high peripheral insulin sensitivity have lower baseline activity in the IPS, but also show the greatest increase in activity in response to insulin. Conversely, those with low peripheral insulin sensitivity maintain a high level of IPS activity in lieu of variable activity in response to insulin.

Finally, we found that the influence of INI versus placebo on caudate connectivity with intraparietal sulcus and bilateral precuneus was associated with working memory ability. The caudate nucleus, which is a primary target of midbrain dopamine neurons is critical for spatial working memory[23]. Research in mice has also shown that impaired insulin signaling in astrocytes can lead to decreased dopamine release in the caudate nucleus and medial prefrontal cortex[22]. This led us to predict that central and peripheral insulin sensitivity may be associated with dopamine dependent cognition via effects on dopaminergic circuit function. Our results are consistent with this possibility. Accordingly, the impaired performance on the spatial working memory was the only effect to survive correction for IQ. This indicates that the poorer performance on the working memory task cannot be accounted for by a generalized cognitive impairment and may reflect involvement of a more specific mechanism like modulation of dopaminergic circuits. Likewise, the pattern of domain specific effects that we observed is consistent with dopamine system involvement. Reaction time index and block design were both impaired and both tasks dependent upon psychomotor/processing speed which is dopamine dependent[47]. One caveat is that spatial working memory performance did not differ between groups on the scanner days. It is not clear if this relates to practice effects or reduced cognitive fatigue since cognitive tests were much shorter on the scanner days.

Limitations

The primary limitation of this study is the small sample size, which was much lower than our target goal and primarily related to the impact of the COVID-19 pandemic on recruitment and retention. Our neuroimaging sample size was further compromised by a high degree of movement artifacts present in this adolescent sample. Overall, this decreased sensitivity likely contributed to our inability to detect impaired central insulin sensitivity. A second weakness is the lack of a healthy weight control group because our funding was specifically targeted to ancillary studies of existing cohorts – here, the PYOD cohort. Finally, causation between differences in IQ and glucose control could not be assessed in this cross-sectional study;

Longitudinal studies assessing change in cognition and metabolic health over time will be critical for resolving this question.

Conclusions and future directions

In conclusion, our study provides strong evidence for the presence of global cognitive impairment in youth with prediabetes that cannot be accounted for by differences in adiposity. We also report a specific deficit in spatial working memory that could not be attributed to the global cognitive impairment. This suggests the existence of both generalized and specific mechanisms contributing to the effects of peripheral metabolic dysfunction on cognition in prediabetes. Since working memory performance was associated with impact of INI on connectivity with the caudate nucleus, which is a primary target of midbrain dopamine neurons, we suggest that the specific mechanism may involve insulin signaling in the dopamine system. Future studies directly testing this are warranted. Future studies should also focus on longitudinal assessment to determine if change in adiposity or peripheral glucose tolerance is associated with change in cognition. This would help to shed light on the causal relationship between cognitive function and diabetes.

Acknowledgements

We would like to thank all participants and project members for their participation in this study.

Funding

This study was funded by R01 DK114169 awarded to D.M.S and S.C. from the National Institute of Health.

Data Availability

De-identified data may be accessed on a case-by-case basis by contacting the corresponding author.

Author's relationships and activities

All authors declare that they have no relationships or activities that might bias, or be perceived to bias, their work on this study.

Contribution statement

SC and DMS were involved in the conception and design of the study. JQ, TA, JS, TK, XD, NS, BP, SC, and DS were involved in the conduct of the study and acquisition of data. JQ, AC, KM, FL, SK, HP NS, FM, AD, SC, and DS were involved in the analysis and interpretation of results. JQ and DMS wrote the first draft of the manuscript with rsFMRI Methods written by AC. All authors edited, reviewed, and approved the final version of the manuscript.

Literature Cited

[1] L. E. Stoeckel *et al.*, "'White Paper' meeting summary and catalyst for future inquiry: Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction," *F1000Research*, vol. 5, p. 353, Mar. 2016, doi: 10.12688/f1000research.8300.1.

[2] G. J. Biessels, M. W. J. Strachan, F. L. J. Visseren, L. J. Kappelle, and R. A. Whitmer, "Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions," *Lancet Diabetes Endocrinol.*, vol. 2, no. 3, pp. 246–255, Mar. 2014, doi: 10.1016/S2213-8587(13)70088-3.

[3] P. S. Koekkoek, L. J. Kappelle, E. van den Berg, G. E. H. M. Rutten, and G. J. Biessels, "Cognitive function in patients with diabetes mellitus: guidance for daily care," *Lancet Neurol.*, vol. 14, no. 3, pp. 329–340, Mar. 2015, doi: 10.1016/S1474-4422(14)70249-2.

[4] Y. You *et al.*, "The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis," *Acta Diabetol.*, vol. 58, no. 6, pp. 671–685, Jun. 2021, doi: 10.1007/s00592-020-01648-9.

[5] H. Sun *et al.*, "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045," *Diabetes Res. Clin. Pract.*, vol. 183, p. 109119, Jan. 2022, doi: 10.1016/j.diabres.2021.109119.

[6] K. L. Ong *et al.*, "Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021," *The Lancet*, vol. 402, no. 10397, pp. 203–234, Jul. 2023, doi: 10.1016/S0140-6736(23)01301-6.

[7] J. M. Lawrence *et al.*, "Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017," *JAMA*, vol. 326, no. 8, pp. 717–727, Aug. 2021, doi: 10.1001/jama.2021.11165.

[8] W. Li and E. Huang, "An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia," *J. Alzheimer's Dis.*, vol. 53, no. 2, pp. 393–402, Jan. 2016, doi: 10.3233/JAD-160114.

[9] M. Xue *et al.*, "Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies," *Ageing Res. Rev.*, vol. 55, p. 100944, Nov. 2019, doi: 10.1016/j.arr.2019.100944.

[10] R. J. McCrimmon, C. M. Ryan, and B. M. Frier, "Diabetes and cognitive dysfunction," *The Lancet*, vol. 379, no. 9833, pp. 2291–2299, Jun. 2012, doi: 10.1016/S0140-6736(12)60360-2.

[11] J. Sripetchwandee, N. Chattipakorn, and S. C. Chattipakorn, "Links Between Obesity-Induced Brain Insulin Resistance, Brain Mitochondrial Dysfunction, and Dementia," *Front. Endocrinol.*, vol. 9, p. 496, Aug. 2018, doi: 10.3389/fendo.2018.00496.

[12] M. A. Fishel *et al.*, "Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults," *Arch. Neurol.*, vol. 62, no. 10, pp. 1539–1544, Oct. 2005, doi: 10.1001/archneur.62.10.noc50112.

[13] R. M. Al Haj Ahmad, N. A. Ababneh, and H. A. Al-Domi, "Brain insulin resistance as a mechanistic mediator links peripheral metabolic disorders with declining cognition," *Diabetes Metab. Syndr. Clin. Res. Rev.*, vol. 16, no. 4, p. 102468, Apr. 2022, doi: 10.1016/j.dsx.2022.102468.

[14] M. Maciejczyk, E. Żebrowska, and A. Chabowski, “Insulin Resistance and Oxidative Stress in the Brain: What’s New?,” *Int. J. Mol. Sci.*, vol. 20, no. 4, 2019, doi: 10.3390/ijms20040874.
[15] J. M. Starr, J. Wardlaw, K. Ferguson, A. MacLullich, I. J. Deary, and I. Marshall, “Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging,” *J. Neurol. Neurosurg. Psychiatry*, vol. 74, no. 1, pp. 70–76, Jan. 2003, doi: 10.1136/jnnp.74.1.70.
[16] S. Craft, “Insulin Resistance and Alzheimer’s Disease Pathogenesis: Potential Mechanisms and Implications for Treatment,” *Curr. Alzheimer Res.*, vol. 4, no. 2, pp. 147–152, Apr. 2007, doi: 10.2174/156720507780362137.
[17] A. Moheet, S. Mangia, and E. R. Seaquist, “Impact of diabetes on cognitive function and brain structure,” *Ann. N. Y. Acad. Sci.*, vol. 1353, no. 1, pp. 60–71, 2015, doi: 10.1111/nyas.12807.
[18] G. A. Şen, S. Tanrıkulu, B. Beşer, Ş. Akçakalem, S. Çakır, and N. Dinççağ, “Effects of prediabetes and type 2 diabetes on cognitive functions,” *Endocrine*, vol. 85, no. 1, pp. 190–195, Jul. 2024, doi: 10.1007/s12020-024-03720-8.
[19] S. Kullmann *et al.*, “Central Insulin Modulates Dopamine Signaling in the Human Striatum,” *J. Clin. Endocrinol. Metab.*, vol. 106, no. 10, Art. no. 10, Oct. 2021, doi: 10.1210/clinem/dgab410.
[20] M. A. Reger *et al.*, “Intranasal insulin improves cognition and modulates β-amyloid in early AD,” *Neurology*, vol. 70, no. 6, pp. 440–448, Feb. 2008, doi: 10.1212/01.WNL.0000265401.62434.36.
[21] S. Craft *et al.*, “Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial,” *Arch. Neurol.*, vol. 69, no. 1, pp. 29–38, Jan. 2012, doi: 10.1001/archneurol.2011.233.
[22] W. Cai *et al.*, “Insulin regulates astrocyte gliotransmission and modulates behavior,” *J. Clin. Invest.*, vol. 128, no. 7, pp. 2914–2926, Jul. 2018, doi: 10.1172/JCI99366.
[23] B. R. Postle and M. D’Esposito, “Dissociation of human caudate nucleus activity in spatial and nonspatial working memory: an event-related fMRI study,” *Cogn. Brain Res.*, vol. 8, no. 2, pp. 107–115, Jul. 1999, doi: 10.1016/S0926-6410(99)00010-5.
[24] W. A. Banks, J. B. Owen, and M. A. Erickson, “Insulin in the brain: there and back again,” *Pharmacol. Ther.*, vol. 136, no. 1, pp. 82–93, Oct. 2012, doi: 10.1016/j.pharmthera.2012.07.006.
[25] S. M. Steculorum, M. Solas, and J. C. Brüning, “The paradox of neuronal insulin action and resistance in the development of aging-associated diseases,” *Alzheimers Dement. J. Alzheimers Assoc.*, vol. 10, no. 1 Suppl, pp. S3-11, Feb. 2014, doi: 10.1016/j.jalz.2013.12.008.
[26] A. M. Stranahan, S. Hao, A. Dey, X. Yu, and B. Baban, “Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice,” *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.*, vol. 36, no. 12, pp. 2108–2121, Dec. 2016, doi: 10.1177/0271678X16642233.
[27] J. Akrivos *et al.*, “Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes,” *Int. J. Geriatr. Psychiatry*, vol. 30, no. 10, pp. 1093–1100, Oct. 2015, doi: 10.1002/gps.4267.
[28] J. J. Ramos-Rodriguez, C. Infante-Garcia, L. Galindo-Gonzalez, Y. Garcia-Molina, A. Lechuga-Sancho, and M. Garcia-Alloza, “Increased Spontaneous Central Bleeding and

Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus," *Mol. Neurobiol.*, vol. 53, no. 4, pp. 2685–2697, May 2016, doi: 10.1007/s12035-015-9311-2.
[29] G. J. Biessels and Y. D. Reijmer, "Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?," *Diabetes*, vol. 63, no. 7, pp. 2244–2252, Jul. 2014, doi: 10.2337/db14-0348.
[30] Z. Zhang *et al.*, "Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies," *Diabetes Care*, vol. 42, no. 7, pp. 1274–1283, Jul. 2019, doi: 10.2337/dc18-2584.
[31] Y. You *et al.*, "The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis," *Acta Diabetol.*, vol. 58, no. 6, pp. 671–685, Jun. 2021, doi: 10.1007/s00592-020-01648-9.
[32] E. Dybjer, P. M. Nilsson, G. Engström, C. Helmer, and K. Nägga, "Pre-diabetes and diabetes are independently associated with adverse cognitive test results: a cross-sectional, population-based study," *BMC Endocr. Disord.*, vol. 18, no. 1, p. 91, Dec. 2018, doi: 10.1186/s12902-018-0318-3.
[33] F. Su *et al.*, "Brain insulin resistance deteriorates cognition by altering the topological features of brain networks," *NeuroImage Clin.*, vol. 13, pp. 280–287, 2017, doi: 10.1016/j.nicl.2016.12.009.
[34] S. Y. Ryu, J.-P. Coutu, H. D. Rosas, and D. H. Salat, "Effects of insulin resistance on white matter microstructure in middle-aged and older adults," *Neurology*, vol. 82, no. 21, pp. 1862–1870, May 2014, doi: 10.1212/WNL.0000000000000452.
[35] X. Tang *et al.*, "Relationship between Central Obesity and the incidence of Cognitive Impairment and Dementia from Cohort Studies Involving 5,060,687 Participants," *Neurosci. Biobehav. Rev.*, vol. 130, pp. 301–313, Nov. 2021, doi: 10.1016/j.neubiorev.2021.08.028.
[36] S. Fitzpatrick, S. Gilbert, and L. Serpell, "Systematic Review: Are Overweight and Obese Individuals Impaired on Behavioural Tasks of Executive Functioning?," *Neuropsychol. Rev.*, vol. 23, no. 2, pp. 138–156, Jun. 2013, doi: 10.1007/s11065-013-9224-7.
[37] L. B. Hassing *et al.*, "Overweight in midlife and risk of dementia: a 40-year follow-up study," *Int. J. Obes.*, vol. 33, no. 8, pp. 893–898, Aug. 2009, doi: 10.1038/ijo.2009.104.
[38] M. Matsuda and R. A. DeFronzo, "Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.," *Diabetes Care*, vol. 22, no. 9, pp. 1462–1470, Sep. 1999, doi: 10.2337/diacare.22.9.1462.
[39] S. Kullmann *et al.*, "Selective Insulin Resistance in Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults," *Diabetes Care*, vol. 38, no. 6, pp. 1044–1050, Mar. 2015, doi: 10.2337/dc14-2319.
[40] Q.-H. Zou *et al.*, "An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: Fractional ALFF," *J. Neurosci. Methods*, vol. 172, no. 1, pp. 137–141, Jul. 2008, doi: 10.1016/j.jneumeth.2008.04.012.
[41] C. Yan and Y. Zang, "DPARSF: a MATLAB toolbox for 'pipeline' data analysis of resting-state fMRI," *Front. Syst. Neurosci.*, vol. 4, May 2010, doi: 10.3389/fnsys.2010.00013.
[42] P. L. Yau *et al.*, "Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus," *Diabetologia*, vol. 53, no. 11, pp. 2298–2306, Nov. 2010, doi: 10.1007/s00125-010-1857-y.

Characteristic	Whole Cohort, N = 66	preT2D-, N = 44	preT2d+, N = 22	*p*-value

[43] B. Antal *et al.*, “Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses,” *eLife*, vol. 11, p. e73138, May 2022, doi: 10.7554/eLife.73138.

[44] A. Cato and T. Hershey, “Cognition and Type 1 Diabetes in Children and Adolescents,” *Diabetes Spectr.*, vol. 29, no. 4, pp. 197–202, Nov. 2016, doi: 10.2337/ds16-0036.

[45] H. A. Allen *et al.*, “Relationship between Parental Feeding Practices and Neural Responses to Food Cues in Adolescents,” *PLOS ONE*, vol. 11, no. 8, p. e0157037, Aug. 2016, doi: 10.1371/journal.pone.0157037.

[46] W. N. Kernan *et al.*, “Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke,” *Neurology*, vol. 60, no. 9, pp. 1447–1451, May 2003, doi: 10.1212/01.WNL.0000063318.66140.A3.

[47] C. Eckart and N. Bunzeck, “Dopamine modulates processing speed in the human mesolimbic system,” *NeuroImage*, vol. 66, pp. 293–300, Feb. 2013, doi: 10.1016/j.neuroimage.2012.11.001.

[48] V. B. Wilson, S. H. Mitchell, E. D. Musser, C. F. Schmitt, and J. T. Nigg, “Delay discounting of reward in ADHD: application in young children,” *J. Child Psychol. Psychiatry*, vol. 52, no. 3, pp. 256–264, 2011, doi: 10.1111/j.1469-7610.2010.02347.x.

[49] R. C. Gur *et al.*, “A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: Standardization and initial construct validation,” *J. Neurosci. Methods*, vol. 187, no. 2, pp. 254–262, Mar. 2010, doi: 10.1016/j.jneumeth.2009.11.017.

[50] H. Francis and R. Stevenson, “Validity and test–retest reliability of a short dietary questionnaire to assess intake of saturated fat and free sugars: a preliminary study,” *J. Hum. Nutr. Diet.*, vol. 26, no. 3, pp. 234–242, 2013, doi: 10.1111/jhn.12008.

Age	14.24 ± 2.47	14.20 ± 2.37	14.32 ± 2.73	0.869[1]
Sex				0.595[2]
Female	39 (59)	25 (57)	14 (64)	
Male	27 (41)	19 ± (43)	8 ± (36)	
Race				0.424[3]
Asian	1 (1.5)	0 (0)	1 (4.5)	
Black/African-American	20 (30)	11 (25)	9 (41)	
White	26 (39)	19 (43)	7 (32)	
More than one race	5 (7.6)	4 (9.1)	1 (4.5)	
Declined to respond	14 (21)	10 (23)	4 (18)	
Ethnicity				>0.999[3]
Latino/Hispanic	30 (45)	20 (45)	10 (45)	
Non-Latino/Hispanic	33 (50)	22 (50)	11 (50)	
Declined to respond	3 (4.5)	2 (4.5)	1 (4.5)	
Full Scale IQ	97 (14)	99 (15)	92 (10)	0.032[1]
Diet (DFS total)	55 (13)	57 (13)	52 (12)	0.114[1]
missing	3	1	2	
BMI	36 ± 7	37 ± 8	35 ± 6	0.486[1]
BMI z-score	2.29 ± 0.42	2.30 ± 0.44	2.29 ± 0.39	0.940[1]
BMI 95th percentile	133 ± 25	134 ± 27	131 ± 21	0.552[1]
Waist to hip ratio	0.88 ± 0.06	0.87 ± 0.06	0.89 ± 0.05	0.278[1]
missing	3	3	0	
Fat mass (kg)	41 ± 14	42 ± 16	39 ± 12	0.388[1]
missing	6	4	2	
Body mass fat percentage	43 ± 7	43 ± 8	43 ± 6	0.808[1]
missing	6	4	2	
Visceral to subcutaneous fat ratio	0.17 ± 0.06	0.16 ± 0.06	0.19 ± 0.06	0.120[1]
missing	4	4	0	
Deep to superficial subcutaneous fat ratio	1.47 ± 0.53	1.55 ± 0.57	1.33 ± 0.44	0.100[1]
missing	4	4	0	
Liver fat fraction	5.3 ± 6.0	4.4 ± 4.8	6.9 ± 7.5	0.153[1]
missing	3	3	0	
Matsuda index	1.44 ± 0.86	1.64 ± 0.97	1.07 ± 0.42	0.002[1]
missing	1	1	0	

Table 1. Demographics, adiposity, and metabolic measures by prediabetes status. Diet (DFS total) is the total combined score on the Dietary Fat and Sugar Questionnaire (DFS) [50].

Domain	Task	Measure	preT2D- sample size	preT2D+ sample size	preT2D- Mean	preT2D+ Mean	Model 1 (no covariates)	Model 2 (IQ included as covariate)		Adjusted Criti Rank Value
							Performance p-value	Performance p-value	IQ p-value	
Executive Function	Spatial Working Memory (CANTAB)	Between Errors	n=29	n=16	24.66‡	40	<0.001*	0.002*	0.11	0.0125
Executive Function	Stop Signal Task (CANTAB)	Signal Reaction Time	n=41	n=21	254.36‡	298.01	0.03	0.091	0.052	0.025
Executive Function	Digit Span (WISC/WAIS)	Scaled Score	n=44	n=22	9.52‡	8.41	0.095	0.51	<0.001	0.0375
Executive Function	Trail Making Test B	Completion Time	n=44	n=22	60.65‡	69.6	0.23	0.51	0.009	0.05
Temporal Discounting	Delayed Discounting	ln(k)	n=33	n=20	-4.4‡	-3.63	0.2	0.56	0.002	0.05
Psychomotor Speed	Reaction Time Index (CANTAB)	Reaction Time	n=42	n=21	251.81‡	291.57	0.01*	0.061	<0.001	0.0167
Psychomotor Speed	Trail Making Test A	Completion Time	n=44	n=22	24.33‡	28.02	0.17	0.33	0.057	0.033
Psychomotor Speed	Coding (WISC/WAIS)	Scaled Score	n=44	n=22	9.64‡	9.18	0.61	0.45	<0.001	0.05
Memory	Pattern Recognition Memory (CANTAB)	Percent Correct	n=26	n=15	77.14‡	65.92	0.060	0.19	0.076	0.025
Memory	Delayed Matching to Sample (CANTAB)	Percent Correct	n=42	n=21	79‡	74.33	0.26	0.45	0.19	0.05
Reasoning and Comprehension	Verbal Comprehension Index (WISC/WAIS)	Composite Score	n=44	n=22	99.36‡	95.14	0.29	0.51	<0.001	0.05
Reasoning and Comprehension	Fluid Reasoning Index (WISC/WAIS)	Composite Score	n=44	n=22	100.82‡	94.05	0.061	0.71	<0.001	0.05
Visuospatial Processing	Block Design (WISC/WAIS)	Scaled Score	n=44	n=22	10.09‡	8.41	0.020*	0.16	<0.001	0.025
Visuospatial Processing	Variable Short Penn Line Orientation Test	Total Positions Off	n=44	n=22	25.34‡	33.62	0.05	0.16	<0.001	0.05

‡ indicates better mean score on a task (not necessarily statistically significant)
* indicates significant difference in performance between groups after multiple comparisons correction

Table 2. Group differences in task performance ‡ indicates better mean performance on a task and * indicates significant difference in performance between groups after multiple comparisons correction. Adjusted Critical Rank Value is the new statistical cutoff for a given test after Benjamini-Hochberg multiple comparisons correction. Tests performed: WISC-V, Wechsler Intelligence Score for Children—Fifth Edition; WAIS-IV, Wechsler Adult Intelligence Scale—

Fourth Edition; CANTAB, Cambridge Neuropsychological Test Automated Battery [CANTAB; Cambridge Cognition Ltd]; Trail Making Test A and B; Delayed Discounting [48]; Variable Short Penn Line Orientation Test [49].

Table 3. Sample size summary for fMRI analyses

Analysis	Scan Timepoints	Sample Size
fMRI: fALFF INI sensitivity and peripheral metabolic health		
3-way full factorial	Pre-spray and post-spray	n=28 preT2D+ n= 9 preT2D- n= 19
Regression with Matsuda index	Post-spay only	n=41
fMRI: fALFF INI sensitivity and cognition		
Spatial working memory	Post-spay only	n=28
Reaction time index	Post-spay only	n=40
Block design	Post-spay only	n=42
fMRI: fALFF and cognition under INI		
Spatial working memory	Post-spay only	n=28
Reaction time index	Post-spay only	n=42
Delayed match-to-sample	Post-spay only	n=42
Pattern recognition memory	Post-spay only	n=27
fMRI: Caudate Connectivity and spatial working memory performance	Post-spay only	n=28



Figure 1. Study Design. (**a**) Overview of whole study timeline, highlighting the four-day Baseline Assessment that the present paper focuses on. (**b**) Resting state fMRI protocol with intranasal insulin and CANTAB cognitive tests. Order of administration of insulin and placebo was counterbalanced between days across participants. Images of cognitive tasks courtesy of CANTAB (© Cambridge Cognition Limited 2025. All rights reserved.)



Figure 2. Participant flow diagram. Participant numbers showing the withdrawals and exclusions from the study from the consenting process, through the baseline assessment, to the analyses.



Figure 3. Correlations matrix of metabolic and adiposity measures. Significant Pearson correlations ($p<0.05$) are marked with an "*". Box color indicates strength and direction of correlation where blue colored boxes indicate a positive relationship between variables and red colored boxes indicate a negative relationship. Abbreviations: Visceral Fat – Visc. Fat; Subcutaneous Fat – SubQ Fat; Visceral fat to subcutaneous fat ratio – Visc/SubQ Ratio; Deep subcutaneous fat – Deep SubQ Fat; Superficial subcutaneous fat – Sup SubQ Fat; Deep subcutaneous fat to superficial subcutaneous fat ratio – Deep/Sup SubQ Ratio.



Figure 4. Baseline differences between groups. Participants with prediabetes had significantly lower Full Scale IQ (**a**) and insulin sensitivity as measured by Matsuda Index (**b**) in Welch Two Sample t-tests. *$p<0.05$



Figure 5. Cognitive function's relation to metabolic health. Participants with prediabetes performed worse on (**a**) the CANTAB Spatial Working Memory Task (SWM, version with 12 boxes), (**b**) CANTAB Reaction Time Index (RTI) task, and (**c**) the WISC/WAIS Block Design (BD) task, as determined by linear regression models. Matsuda index is negatively correlated with (**d**) RTI and (**e**) Trail Making Test A (TMT A) task performance in linear regression models with age and BMI z-score as covariates. * indicates significance after multiple comparisons correction, ‡ indicates significance after including IQ in the regression model and multiple comparisons correction.



Figure 6. Peripheral metabolism effects on resting state brain activity. (**a**) Peak beta values from the IPS cluster in **b** for each group. (**b**) Full Factorial group effect of preT2D+ group > preT2D- group in left intraparietal sulcus (IPS, Montreal Neurological Institute [MNI] coordinates: -26, -42, 40). (**c**) Full factorial three-way interaction shows preT2D- group had a greater increase in resting state activity (Insulin [Pre – Post] – Placebo [Pre- Post]) in the right occipital cortex (MNI coordinates: 30 -84 22) compared to preT2D+ group. (**d**) Correlation between Matsuda Index and response to INI in the left intraparietal sulcus (MNI coordinates: -26 -52 40). (**e**) Plotted values of the peak voxel from the cluster in **d** from the Insulin – Placebo map against Matsuda index. *p<0.05



Figure 7. Brain sensitivity to INI related to cognitive performance. (**a**) Right medial anterior prefrontal cortex (MNI coordinates: 12 56 2) INI sensitivity is negatively correlated with Reaction Time Index performance in whole cohort. Non-significant anterior medial prefrontal cortex cluster (MNI coordinates: 8 64 14) in regression of preT2D+ group RTI performance and INI sensitivity. (MNI coordinates: 12 58 4) Significant anterior medial prefrontal cortex cluster (MNI coordinates: 8 64 14) in regression of preT2D- group RTI performance and INI sensitivity. (**b**) Plotted values of the peak voxel from the whole cohort cluster in **a**. (**c**) Left supratemporal gyrus (MNI coordinates: -40 0 -14) INI sensitivity negatively correlated with RTI performance INI sensitivity. (**d**) Plotted values of the peak voxel from the cluster in **c**. (**e**) Left Insula (MNI coordinates: -38 0 12) INI sensitivity positively correlated with Pattern recognition memory INI sensitivity. (**f**) Plotted values of the peak voxel from the cluster in **e**.



Figure 8. Caudate Connectivity sensitivity to INI associated with Spatial Working Memory. (**a**) Right intraparietal sulcus (MNI coordinates: 38 -56 58) and bilateral precuneus (MNI coordinates: 6 -62 44) connectivity with the caudate for insulin minus placebo shows a negative correlation with errors made on SWM task. (**b**) Plotted values of the peak voxel from the IPS cluster in A from the Insulin – Placebo map against SWM errors. (**c**) Plotted values of the peak voxel from the bilateral caudate cluster in **a**. (**d**) Left precuneus (MNI coordinates: -8 -76 52), right precuneus (MNI coordinates: 16 -68 44), left intraparietal sulcus (MNI coordinates: -38 -52 40), right dorsolateral prefrontal cortex (MNI coordinates: 40 30 30), and right fusiform (MNI coordinates: 34 -38 -16) caudate connectivity for insulin minus placebo in preT2D- are correlated with errors made on SWM task.

h